论文部分内容阅读
目的评价连续性血液净化技术在重症医学中的应用效果。方法回顾性分析83例接受连续性血液净化治疗患者的临床资料,记录患者治疗后的情况。结果 83例患者中,33例痊愈,31例好转,19例死亡,死亡率为22.89%。19例死亡患者中,2例为恶性血液疾病患者,4例为脓毒症并多脏器衰竭患者(包括肾衰竭),8例为重度心力衰竭伴肾衰竭患者,5例为肾衰竭患者。47例未死亡肾衰竭患者治疗前后血肌酐值、血尿素氮比较,差异具有统计学意义(P<0.05)。10例未死亡脓毒症患者治疗后体温为(36.63±0.60)℃,明显低于治疗前的(38.20±0.91)℃,差异具有统计学意义(P<0.05)。死亡患者急性生理学与慢性健康状况评分(APACHEII评分)为(29.74±2.57)分,明显高于未死亡患者的(22.09±2.47)分,且死亡患者ICU住院时间为(13.31±8.18)d,明显多于未死亡患者的(9.89±5.50)d,差异均具有统计学意义(P<0.05)。结论连续性血液净化技术在重症医学中的广泛应用,可有效救治重症患者。
Objective To evaluate the application effect of continuous blood purification in critical care. Methods A retrospective analysis of 83 patients undergoing continuous blood purification treatment of clinical data, record the patient after treatment. Results Of 83 patients, 33 recovered, 31 improved, and 19 died, with a mortality rate of 22.89%. Of the 19 deaths, 2 were patients with hematologic malignancies, 4 were sepsis with multiple organ failure (including renal failure), 8 were patients with severe heart failure and renal failure, and 5 were renal failure patients. The serum creatinine and blood urea nitrogen in 47 cases of non-death renal failure before and after treatment were significantly different (P <0.05). The body temperature of the 10 patients without death sepsis after treatment was (36.63 ± 0.60) ℃, which was significantly lower than that before treatment (38.20 ± 0.91) ℃, the difference was statistically significant (P <0.05). The APACHEII score of death patients was (29.74 ± 2.57) points, which was significantly higher than that of non-death patients (22.09 ± 2.47), and the hospital stay of ICU was (13.31 ± 8.18) days More than those without death (9.89 ± 5.50) d, the differences were statistically significant (P <0.05). Conclusion Continuous blood purification technology is widely used in critical care, which can effectively treat critically ill patients.